Maternal Supplementation with N-Acetylcysteine Modulates the Microbiota-Gut-Brain Axis in Offspring of the Poly I:C Rat Model of Schizophrenia.
Poly I:C
inflammation
microbiota-gut-brain axis
oxidative stress
schizophrenia
Journal
Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981
Informations de publication
Date de publication:
20 Apr 2023
20 Apr 2023
Historique:
received:
01
02
2023
revised:
03
04
2023
accepted:
04
04
2023
medline:
28
4
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
The microbiota-gut-brain axis is a complex interconnected system altered in schizophrenia. The antioxidant N-acetylcysteine (NAC) has been proposed as an adjunctive therapy to antipsychotics in clinical trials, but its role in the microbiota-gut-brain axis has not been sufficiently explored. We aimed to describe the effect of NAC administration during pregnancy on the gut-brain axis in the offspring from the maternal immune stimulation (MIS) animal model of schizophrenia. Pregnant Wistar rats were treated with PolyI:C/Saline. Six groups of animals were studied according to the study factors: phenotype (Saline, MIS) and treatment (no NAC, NAC 7 days, NAC 21 days). Offspring were subjected to the novel object recognition test and were scanned using MRI. Caecum contents were used for metagenomics 16S rRNA sequencing. NAC treatment prevented hippocampal volume reduction and long-term memory deficits in MIS-offspring. In addition, MIS-animals showed lower bacterial richness, which was prevented by NAC. Moreover, NAC7/NAC21 treatments resulted in a reduction of proinflammatory taxons in MIS-animals and an increase in taxa known to produce anti-inflammatory metabolites. Early approaches, like this one, with anti-inflammatory/anti-oxidative compounds, especially in neurodevelopmental disorders with an inflammatory/oxidative basis, may be useful in modulating bacterial microbiota, hippocampal size, as well as hippocampal-based memory impairments.
Identifiants
pubmed: 37107344
pii: antiox12040970
doi: 10.3390/antiox12040970
pmc: PMC10136134
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, co-financed by the European Regional Development Fund (ERDF), "A way to make Europe"
ID : project number PI17/01766, and grant number BA21/00030
Organisme : MCIN /AEI /10.13039/501100011033 / FEDER, UE
ID : project PID2021-128862OB-I00
Organisme : CIBER de Salud Mental - Instituto de Salud Carlos III
ID : project number CB07/09/0031
Organisme : Delegación del Gobierno para el Plan Nacional sobre Drogas
ID : project numbers 2017/085, 2022/008917
Organisme : Fundación Alicia Koplowitz
ID : 2016/01
Organisme : Consejería de Educación e investigación, Comunidad de Madrid, co-funded by the European Social Fund "Investing in your future"
ID : grant, PEJD-2018-PRE/BMD-7899
Organisme : Instituto de investigación Sanitaria Gregorio Marañón
ID : "Programa Intramural de Impulso a la I+D+I 2019"
Organisme : Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III
ID : PT20/00044
Organisme : The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505)
ID : x
Organisme : FINBA
ID : Contrato Intramural Postdoctoral
Organisme : Ayudas para grupos de investigación de organismos del Principado de Asturias
ID : SV-PA-21-AYUD/2021/51347
Références
Antioxidants (Basel). 2021 Feb 05;10(2):
pubmed: 33562763
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 8;105:110130
pubmed: 33045322
Schizophr Res. 2018 Feb;192:398-403
pubmed: 28442250
Antioxid Redox Signal. 2013 Apr 20;18(12):1428-43
pubmed: 22938092
Pharmacotherapy. 2017 Mar;37(3):261-267
pubmed: 28035686
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Aug 30;110:110306
pubmed: 33745977
Exp Neurol. 2016 Sep;283(Pt A):142-50
pubmed: 27302677
Neurogastroenterol Motil. 2011 Feb;23(2):169-77, e41-2
pubmed: 21129126
Front Pharmacol. 2022 Jul 26;13:886514
pubmed: 35959428
Front Behav Neurosci. 2023 Jan 06;16:1022622
pubmed: 36733452
Br J Psychiatry. 2014 Nov;205(5):369-75
pubmed: 25213158
Food Funct. 2019 Feb 20;10(2):691-702
pubmed: 30663724
PeerJ. 2015 Aug 25;3:e1140
pubmed: 26336637
Antioxidants (Basel). 2020 Sep 13;9(9):
pubmed: 32933169
Trends Pharmacol Sci. 2013 Mar;34(3):167-77
pubmed: 23369637
Food Funct. 2022 Mar 21;13(6):3368-3380
pubmed: 35229847
Front Neurosci. 2015 Oct 21;9:372
pubmed: 26539073
Schizophr Res. 2015 Aug;166(1-3):238-47
pubmed: 26055633
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:289-296
pubmed: 29126981
Mol Psychiatry. 2016 Jun;21(6):738-48
pubmed: 27090305
JAMA Psychiatry. 2021 Dec 1;78(12):1343-1354
pubmed: 34524405
Annu Rev Neurosci. 2017 Jul 25;40:21-49
pubmed: 28301775
J Anim Sci. 2019 Apr 3;97(4):1757-1771
pubmed: 30789643
HRB Open Res. 2021 Sep 29;4:108
pubmed: 34870091
Eur Neuropsychopharmacol. 2021 May;46:14-27
pubmed: 33735708
Microorganisms. 2019 Jan 10;7(1):
pubmed: 30634578
J Diabetes. 2019 Jan;11(1):32-45
pubmed: 29845722
Eur Neuropsychopharmacol. 2019 Jul;29(7):880-896
pubmed: 31229322
CNS Neurosci Ther. 2022 Dec 5;:
pubmed: 36468448
Int J Neuropsychopharmacol. 2017 Dec 1;20(12):988-993
pubmed: 29016806
Behav Brain Res. 2011 Nov 20;225(1):382-7
pubmed: 21816179
Cell. 2014 Mar 27;157(1):121-41
pubmed: 24679531
Neuropharmacology. 2016 Apr;103:122-33
pubmed: 26686392
Nutrients. 2020 May 19;12(5):
pubmed: 32438689
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Aug 30;102:109951
pubmed: 32335265
Behav Brain Res. 2020 Feb 3;379:112374
pubmed: 31759045
Schizophr Res. 2013 Aug;148(1-3):130-7
pubmed: 23746484
Genes (Basel). 2018 Mar 01;9(3):
pubmed: 29494510
Front Cell Infect Microbiol. 2021 Jan 27;10:611014
pubmed: 33585279
Sci Adv. 2019 Feb 06;5(2):eaau8317
pubmed: 30775438
Brain Sci. 2021 Sep 30;11(10):
pubmed: 34679364
Front Psychiatry. 2020 Mar 12;11:156
pubmed: 32226399
Neurochem Res. 2013 Feb;38(2):433-42
pubmed: 23212700
Front Cell Infect Microbiol. 2022 Mar 14;12:831666
pubmed: 35360098
Mol Psychiatry. 2018 Apr;23(4):943-951
pubmed: 28373685
Mol Neurobiol. 2020 Oct;57(10):4345-4361
pubmed: 32720073
J Neural Transm (Vienna). 2002 May;109(5-6):891-905
pubmed: 12111476
Brain Behav. 2021 May;11(5):e02133
pubmed: 33793085
J Neurogastroenterol Motil. 2017 Oct 30;23(4):555-560
pubmed: 28738451
Int J Neuropsychopharmacol. 2021 Sep 21;24(9):734-748
pubmed: 34165516
Schizophr Res. 2022 Sep;247:92-100
pubmed: 34483026
Nat Neurosci. 2017 Oct 26;20(11):1434-1447
pubmed: 29073641
Transl Psychiatry. 2017 May 9;7(5):e1120
pubmed: 28485733
Neuropsychopharmacol Rep. 2022 Mar;42(1):70-76
pubmed: 35080340
Nutrients. 2021 Mar 31;13(4):
pubmed: 33807241
Mol Psychiatry. 2019 May;24(5):633-642
pubmed: 30242229
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3;57:69-75
pubmed: 25315856
Cell. 2013 Dec 19;155(7):1451-63
pubmed: 24315484
PLoS Biol. 2020 Jul 14;18(7):e3000410
pubmed: 32663219
Front Psychiatry. 2020 Aug 11;11:799
pubmed: 32903683
PLoS One. 2010 Feb 05;5(2):e9085
pubmed: 20140211
Curr Opin Gastroenterol. 2021 May 1;37(3):179-186
pubmed: 33769374
Ther Adv Psychopharmacol. 2022 May 15;12:20451253221096525
pubmed: 35600753
Neuropsychopharmacology. 2017 Jun;42(7):1435-1446
pubmed: 28102228
Ann Thorac Surg. 2016 May;101(5):1644-5
pubmed: 27106412
Microorganisms. 2022 May 29;10(6):
pubmed: 35744639